Pfizer Inc. $PFE Shares Sold by Woodstock Corp

Woodstock Corp lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,007 shares of the biopharmaceutical company’s stock after selling 3,250 shares during the quarter. Woodstock Corp’s holdings in Pfizer were worth $2,473,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter valued at approximately $27,000. North Capital Inc. acquired a new position in Pfizer during the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Finally, Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 0.5%

Shares of Pfizer stock opened at $23.98 on Tuesday. The stock’s fifty day moving average is $24.76 and its 200-day moving average is $24.25. The firm has a market capitalization of $136.34 billion, a PE ratio of 12.76, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.